ANN IGOE: Open Payments
NPI 1972060960 · YPSILANTI, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$405 in 20 payments from 7 companies in 2025. Trend: 2023 $770 · 2024 $501 · 2025 $405
Food & beverage: $405
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $181 |
| Neurocrine BioSciences, Inc. | 4 | $75 |
| Alkermes, Inc. | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| E.R. Squibb & Sons, L.L.C. | 2 | $30 |
| Lundbeck LLC | 1 | $16 |
| Janssen Pharmaceuticals, Inc | 1 | $15 |
Products named: CAPLYTA, INGREZZA, ARISTADA, REXULTI, COBENFY, ABILIFY ASIMTUFII, INVEGA SUSTENNA.
Industry payments across MI — which companies pay providers there.
